Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

R&D Execs Paint Bleak Picture Of Industry Productivity: $1.4 Bil. Per NME

Executive Summary

Pharmaceutical R&D execs estimate the cost of drug development to be $1.4 bil. per new molecular entity, Wyeth R&D President Robert Ruffolo, PhD, told an IBC conference in Boston Aug. 12

You may also be interested in...



Levitra Is Big News On Wall Street, But Rx Firms Ask Investors To Think Small

GlaxoSmithKline's levitating act in the third quarter shows that co-promotion deals have kept their magic for the company

Levitra Is Big News On Wall Street, But Rx Firms Ask Investors To Think Small

GlaxoSmithKline's levitating act in the third quarter shows that co-promotion deals have kept their magic for the company

R&D Cost Estimate Should Be Studied By FDA, Rep. Brown Tells Commissioner

FDA should gather its own data on the cost of drug development rather than repeat the industry estimate of $800 mil. per new molecular entity, Rep. Sherrod Brown (D-Ohio) told an IIR conference on generic drugs Oct. 1 in Washington, D.C

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS042336

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel